AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Popularity #717Earnings are out

ABVX · NASDAQ · Biotechnology

Abivax (ADR) (ABVX)

Develops oral obefazimod for ulcerative colitis and Crohn's disease.

$98.73

After hours+0.46 (+0.47%)

At close$98.27(−5.01%)

In millions of USD, except per-share figures · converted from EUR at the latest rate

In millions	Q2 FY20Jun 2020	Q4 FY20Dec 2020	Q2 FY21Jun 2021	Q4 FY21Dec 2021	Q2 FY22Jun 2022	Q4 FY22Dec 2022	Q2 FY23Jun 2023	Q4 FY23Dec 2023	Q2 FY24Jun 2024	Q4 FY24Dec 2024	Q2 FY25Jun 2025	Q4 FY25Dec 2025
Revenue	0	0	0	0	3	3	3	3	0	0	0	0
Cost of revenue	0	0	0	0	0	0	0	0	0	0	0	0
Gross profit	0	0	0	0	3	3	3	3	0	0	0	0
	19	27	30	29	32	44	45	105	40	54	53	229
Research & development	15	24	27	27	17	38	37	81	33	45	44	51
	3	3	3	3	3	6	8	25	14	10	10	32
Selling & marketing	0	0	0	0	0	0	0	7	0	0	0	0
General & administrative	0	0	0	0	3	6	8	18	13	10	10	32
Other expenses	0	0	0	0	13	0	0	0	−6	−1	−1	146
Operating income	−19	−27	−30	−29	−21	−44	−45	−106	−40	−54	−53	−229
	1	−2	10	−2	−15	−5	−17	−6	−4	−6	−2	−94
Interest income	0	0	0	0	0	0	0	0	3	1	0	1
Interest expense	1	2	1	2	2	2	17	7	4	5	4	17
Other non-operating income	0	0	0	−1	−13	−3	0	0	0	1	−2	66
Income before tax	−18	−28	−21	−31	−36	−49	−62	−112	−44	−60	−55	−323
Income tax expense	0	−3	−2	−3	−3	−3	−3	−3	0	0	0	7
Net income from continuing operations	−18	−25	−19	−28	−34	−46	−60	−110	−44	−60	−55	−330
Other adjustments	0	0	0	0	0	0	0	0	0	0	0	0
Net income	−18	−25	−19	−28	−34	−46	−60	−110	−44	−60	−55	−330
EPS, basic	−$1.44	−$1.78	−$1.29	−$1.70	−$2.02	−$2.07	−$1.66	−$2.27	−$0.74	−$1.72	−$1.82	−$2.41
EPS, diluted	−$1.44	−$1.78	−$1.29	−$1.70	−$2.02	−$2.07	−$1.66	−$2.27	−$0.74	−$1.72	−$1.82	−$2.41
Weighted average shares, basic	12	14	15	17	17	22	36	48	63	63	63	70
Weighted average shares, diluted	12	14	15	17	17	22	36	48	63	63	63	70
EBITDA	−19	−27	−30	−29	−17	−41	−45	−105	−40	−54	−51	−293
Depreciation & amortization	0	0	0	0	0	0	0	0	0	0	0	1
EBIT	−19	−27	−30	−29	−17	−41	−45	−106	−40	−55	−51	−294